{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T16:52:08Z","timestamp":1788454328498,"version":"build-2803163510"},"reference-count":6,"publisher":"Society of Nuclear Medicine","issue":"Supplement 1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Nucl. Med.\n                Technol."],"accepted":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2025,12]]},"DOI":"10.2967\/jnmt.125.271067","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:40:17Z","timestamp":1764855617000},"page":"144S-149S","source":"Crossref","is-referenced-by-count":4,"title":["Theranostics Finances and Coding of Today and a Look Forward"],"prefix":"10.2967","volume":"53","author":[{"given":"Dmitry","family":"Beyder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2025121109350927000_53.Supplement_1.144S.1","unstructured":"Radioligand Therapy (RLT) Market Size, Share, Trends and Forecast 2030. PharmiWeb website. https:\/\/www.pharmiweb.com\/press-release\/2025-10-29\/radioligand-therapy-rlt-market-size-share-trends-and-forecast-2030#:\u223c:text=Radioligand%20Therapy%20(RLT)%20Market%20Overview,quick%20inquiry%20for%20a%20sample. Published October 29, 2025. Accessed November 9, 2025."},{"key":"2025121109350927000_53.Supplement_1.144S.2","unstructured":"Novartis Pharmaceuticals Corporation. Pluvicto [package insert]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf. Revised March 2022. Accessed November 9, 2025."},{"key":"2025121109350927000_53.Supplement_1.144S.3","unstructured":"Advanced Accelerator Applications USA, Inc. Lutathera [package insert]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208700s000lbl.pdf. Revised 2024. Accessed November 9, 2025."},{"key":"2025121109350927000_53.Supplement_1.144S.4","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Xofigo [package insert ]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203971s016lbl.pdf. Revised December 2019. Accessed November 9, 2025."},{"key":"2025121109350927000_53.Supplement_1.144S.5","unstructured":"Progenics Pharmaceuticals, Inc. Azedra [package insert]. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209607s000lbl.pdf. Revised July 2018. Accessed November 9, 2025."},{"key":"2025121109350927000_53.Supplement_1.144S.6","unstructured":"Future of Theranostics: White Paper from the Theranostics Stakeholders Summit, May 1\u20133, 2025. Reston, VA: SNMMI; 2025. https:\/\/acnmonline.org\/common\/Uploaded%20files\/News\/Theranostics_Stakeholders_Summit_White_Paper_FINAL_6-2025.pdf. Accessed November 9, 2025."}],"container-title":["Journal of Nuclear Medicine Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnmt.125.271067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:35:22Z","timestamp":1765474522000},"score":1,"resource":{"primary":{"URL":"http:\/\/tech.snmjournals.org\/lookup\/doi\/10.2967\/jnmt.125.271067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":6,"journal-issue":{"issue":"Supplement 1","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.2967\/jnmt.125.271067"],"URL":"https:\/\/doi.org\/10.2967\/jnmt.125.271067","relation":{},"ISSN":["0091-4916","1535-5675"],"issn-type":[{"value":"0091-4916","type":"print"},{"value":"1535-5675","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}